DEL VECCHIO, SILVANA
 Distribuzione geografica
Continente #
AS - Asia 5.364
NA - Nord America 4.585
EU - Europa 3.206
SA - Sud America 589
Continente sconosciuto - Info sul continente non disponibili 197
AF - Africa 171
OC - Oceania 6
Totale 14.118
Nazione #
US - Stati Uniti d'America 4.398
SG - Singapore 2.527
RU - Federazione Russa 1.473
VN - Vietnam 940
CN - Cina 931
IT - Italia 507
BR - Brasile 456
HK - Hong Kong 436
DE - Germania 204
FR - Francia 192
UA - Ucraina 164
FI - Finlandia 149
IE - Irlanda 121
CA - Canada 98
BD - Bangladesh 97
GB - Regno Unito 91
IN - India 83
SE - Svezia 80
JP - Giappone 74
NL - Olanda 65
BE - Belgio 58
AR - Argentina 57
MX - Messico 50
CI - Costa d'Avorio 49
KR - Corea 42
ZA - Sudafrica 37
PH - Filippine 30
IQ - Iraq 29
TH - Thailandia 24
PL - Polonia 22
AT - Austria 21
EC - Ecuador 21
TR - Turchia 17
ID - Indonesia 16
MA - Marocco 16
TW - Taiwan 15
VE - Venezuela 15
TN - Tunisia 14
CO - Colombia 11
LT - Lituania 11
ES - Italia 10
EG - Egitto 9
PY - Paraguay 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
DZ - Algeria 8
KZ - Kazakistan 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
DO - Repubblica Dominicana 7
HN - Honduras 7
JO - Giordania 6
MY - Malesia 6
NP - Nepal 6
PE - Perù 6
SN - Senegal 6
AZ - Azerbaigian 5
KE - Kenya 5
OM - Oman 5
BG - Bulgaria 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
GH - Ghana 4
IR - Iran 4
IS - Islanda 4
JM - Giamaica 4
AM - Armenia 3
AU - Australia 3
BO - Bolivia 3
CG - Congo 3
ET - Etiopia 3
GE - Georgia 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
PA - Panama 3
QA - Qatar 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BB - Barbados 2
BJ - Benin 2
BZ - Belize 2
DK - Danimarca 2
EU - Europa 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
BA - Bosnia-Erzegovina 1
Totale 13.891
Città #
Singapore 1.172
San Jose 696
Hong Kong 423
Moscow 360
Chandler 322
Ashburn 301
Ho Chi Minh City 271
Beijing 225
Hanoi 204
Jacksonville 201
Santa Clara 171
The Dalles 142
Lauterbourg 138
Boston 129
Princeton 126
Naples 125
Los Angeles 124
Millbury 124
Woodbridge 107
Nanjing 88
Buffalo 71
Wilmington 69
Hefei 68
Tokyo 65
Amsterdam 53
New York 53
Da Nang 52
Houston 51
Brussels 48
Haiphong 45
Redondo Beach 41
Council Bluffs 40
Ottawa 40
Dallas 38
Munich 36
Des Moines 35
Seattle 35
São Paulo 35
Ann Arbor 34
Nanchang 34
Tianjin 33
Chicago 31
Orem 29
Napoli 28
Hebei 27
Shenyang 26
Nuremberg 25
Frankfurt am Main 24
Dublin 22
Milan 22
Lawrence 21
Changsha 20
Mexico City 20
Rome 20
Jiaxing 19
Brooklyn 18
Norwalk 18
Biên Hòa 17
San Francisco 17
Montreal 15
Seoul 15
Toronto 15
Baghdad 14
Hải Dương 14
London 14
Warsaw 14
Atlanta 13
Boardman 13
Denver 13
Kochi 13
Stockholm 13
Turku 13
Dong Ket 12
Falls Church 12
Chennai 10
Curitiba 10
Helsinki 10
Kronberg 10
Phoenix 10
Pune 10
Zhengzhou 10
Belo Horizonte 9
Falkenstein 9
Guayaquil 9
Johannesburg 9
Poplar 9
Quận Bình Thạnh 9
Rio de Janeiro 9
Thái Bình 9
Can Tho 8
Guangzhou 8
Kunming 8
Manchester 8
Mumbai 8
Washington 8
Charlotte 7
Columbus 7
Lappeenranta 7
Tashkent 7
Thái Nguyên 7
Totale 7.257
Nome #
2-deoxy-2[F-18] fluoro-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma 188
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 186
Tumor induced osteomalacia: a systematic review and individual patient's data analysis 179
Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients 178
Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors. 157
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 153
Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma 153
Prediction of 2-[18F]FDG PET-CT SUVmax for Adrenal Mass Characterization: A CT Radiomics Feasibility Study 149
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms 143
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 143
Investigation of integrin expression in cancer stem cells isolated from glioblastoma patients 140
ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors 138
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 136
2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis 136
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer 134
Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides 133
Coefficient of variation in metastatic lymph nodes determined by 18F-FDG PET/CT in patients with advanced NSCLC: combination with coefficient of variation in primary tumors 132
Impact of COVID-19 pandemic on 2-[18F]FDG PET/CT imaging work-flow in a single medical institution: comparison among the three Italian waves 132
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 122
Distribution of mediastinal lesions across multi-institutional, international, radiology databases 122
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma 121
Epidermal growth factor (EGFR) and Transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells. 120
Metabolic tumor volume assessed by 18F-FDG-PET/CT for the prediction of outcome in patients with multiple myeloma 120
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study 119
Washout of 99mTc-Sestamibi in predicting response to chemotherapy in patients with multiple myeloma. 118
Oncologia 118
FDG-PET/CT imaging during the Covid-19 emergency: a southern Italian perspective 118
Functional imaging of multidrug resistance in breast cancer. 117
Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial 116
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 115
Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma 115
Non-canonical role of PDK1 as a negative regulator of apoptosis through macromolecular complexes assembly at the ER-mitochondria interface in oncogene-driven NSCLC 114
Neutrophil extracellular traps as an adhesion substrate for different tumor cells expressing RGD-binding integrins. 112
Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells 112
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. 111
Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw 108
99mTc-MIBI in the evaluation of breast cancer biology 107
Nuclear imaging in cancer theranostic 107
PET/CT in cancer research: from preclinical to clinical applications. 105
Permeabilità bronchiale transepiteliale. Basi funzionali ed implicazioni cliniche. 105
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma 103
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the evaluation of patients with multiple myeloma 102
F-18-FDG-PET/CT, 99mTC-MIBI and MRI in the evaluation of patients with multiple myeloma 102
Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. 101
99mTc-MIBI uptake in Bcl-2 overexpressing non-Hodgkin's lymphoma patients during drug-induced apoptosis. 100
Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. 99
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcima 99
99mTc-MIBI in the evaluation of breast cancer biology 99
Combined imaging with 18F-FDG-PET/CT and 111In-labeled Octreotide SPECT for evaluation of thymic epithelial tumors 99
Brain metastases unresponsive to immunotherapy detected by 18F-FDG-PET/CT in a patient with melanoma 99
Tc99m-sestaMIBI uptake in nonsecretory multiple myeloma 98
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. 98
La Medicina Nucleare in Oncologia 97
18F-FDG-PET/CT in the evaluation of bone marrow infiltration in patients with multiple myeloma. 96
99mTc-MIBI uptake in breast cancer cells during early phases of apoptosis induction with Staurosporine 95
Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients 94
Detection of leptomeningeal involvement by 18F-FDG-PET/CT in a patient with non-Hodgkin lymphoma 94
What molecular imaging of cancer patients can teach us about COVID-19 93
Nuclear Imaging of Apoptosis in Animal Tumor Models 92
Urokinase receptor interacts with avb5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer 92
Scintigraphic detection of multidrug resistance in cancer 91
European Association of Nuclear Medicine 91
Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells 90
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma 89
Radiolabeling approches for cholecystokinin B receptor imaging 89
Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers 88
PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients 88
Molecular imaging of tumor microenvironment: challenges and perspectives 87
SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer 86
Preclinical imaging in targeted cancer therapies. 85
In vitro receptor imaging for characterization of human solid tumors. 85
Combined SPECT/CT and PET/CT for breast imaging 85
Detection of colon cancer with radiolabelled monoclonal antibodies. 84
Vitronectin binding to urokinase receptor in human breast carcinoma 83
Mammoscintigrafia e carcinoma mammario 83
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. 82
99mTc-MIBI uptake is reduced in Bcl-2 overexpressing MCF-7 breast cancer cells 82
Metabolic Tumor Volume assessed by 18F-FDG-PET/CT in the evaluation of plasma cell mass and prediction of outcome in patients with multiple myeloma. 82
Technetium 99m sestamibi in multiple myeloma 81
Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up 81
111In-pentetreotide scintigraphy:procedure guidelines for tumor imaging 81
Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. 80
Annual Congress of the European Association of Nuclear Medicine Munich 2008 79
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells. 79
Scintimammography with 99mTc-MIBI versus dynamic MRI forn non-invasive characterization of breast masses 78
Fractional retention of 99mTc-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. 77
MIBI as prognostic factor in breast cancer 76
A new role for nuclear medicine in multiple myeloma. 76
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. 76
Molecular imaging: High-resolution detectors for early diagnosis and therapy monitoring of breast cancer. 75
A reversible shift of driver dependence from EGFR to Notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors. 75
Use of 99mTc-sestamibi scintigraphy in multiple myeloma 74
Tumor clearance of Technetium 99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer 74
Avid (67)Ga uptake in multiple myeloma relapsing after bone marrow transplant. 74
Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. 74
Texture Analysis of 68Ga-DOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors 73
In vivo detection of multidrug-resistant (MDR1) phenotype by 99mTc-Sestamibi scan in untreated breast cancer patients. 73
Evaluation of the side effects of chemotherapy and radiotherapy on other organs 73
Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer. 73
Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with αvβ5. 73
Totale 10.409
Categoria #
all - tutte 51.454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.454


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022712 0 1 7 1 10 29 11 22 114 38 145 334
2022/2023769 162 57 14 64 95 88 4 71 122 48 38 6
2023/2024616 43 82 65 41 41 22 23 83 24 20 119 53
2024/20253.490 215 273 11 41 84 151 445 215 251 385 1.137 282
2025/20266.845 691 414 677 559 1.325 272 627 488 947 455 167 223
2026/2027210 153 57 0 0 0 0 0 0 0 0 0 0
Totale 14.118